AGÕæÈ˹ٷ½

Insider Trading Alert: Allogene Therapeutics (ALLO) Director Vicki L. Sato received a significant stock option grant on June 18, 2025. The transaction details reveal:

• Granted 144,400 stock options to purchase common stock
• Exercise price set at $1.29 per share
• Options expire on June 18, 2035
• Vesting schedule: Equal monthly installments over 12 months

This Form 4 filing indicates a standard director compensation package through equity incentives. The relatively low exercise price and extended 10-year expiration term suggest a long-term alignment with shareholder interests. The monthly vesting schedule encourages continued service on the board. The transaction was executed directly, with no indirect ownership reported.

Allogene Therapeutics (ALLO) director Deborah M. Messemer received a significant equity grant on June 18, 2025. The insider was awarded 95,400 Restricted Stock Units (RSUs) with the following key terms:

• RSUs will vest in two equal semi-annual installments over one year from grant date
• Each RSU represents a right to receive one share of common stock
• Grant price was $0, as typical for RSU awards
• Director elected to defer receipt of shares until either:
  • 30 days after Board separation
  • Company change in control

This Form 4 filing represents standard non-employee director compensation and demonstrates continued alignment between board member and shareholder interests through equity-based compensation.

Franz B. Humer, Director at Allogene Therapeutics (ALLO), received a grant of 95,400 Restricted Stock Units (RSUs) on June 18, 2025. The RSUs represent the right to receive an equivalent number of common stock shares.

Key terms of the RSU grant:

• Vesting Schedule: Equal semi-annual installments over one year from grant date
• Exercise Price: $0
• Special Deferral: Humer elected to defer receipt of shares until either:
• 30 days after Board separation, or
• Company change in control

This Form 4 filing was submitted by Earl Douglas (Attorney-in-fact) on June 20, 2025, reporting the transaction under Section 16(a) of the Securities Exchange Act. The grant appears to be part of the company's Non-Employee Director Compensation Policy.

Elizabeth A. Barrett, Director of Allogene Therapeutics (ALLO), received a significant equity grant on June 18, 2025. The transaction involved the acquisition of 95,400 Restricted Stock Units (RSUs) with a $0 exercise price.

Key terms of the RSU grant:

• Vesting occurs in two equal semi-annual installments over one year from grant date
• Each RSU converts to one share of common stock
• Barrett elected to defer receipt of shares until either:
  • 30 days after Board separation
  • Company change in control

The grant represents part of the company's Non-Employee Director Compensation Policy. The filing was executed by Earl Douglas as Attorney-in-Fact on June 20, 2025.

Allogene Therapeutics (ALLO) director Stephen Mayo received a significant equity grant on June 18, 2025, consisting of 95,400 Restricted Stock Units (RSUs). The RSUs will vest in two equal semi-annual installments over a one-year period from the grant date.

Key terms of the RSU grant:

• Each RSU represents one share of common stock
• Grant price: $0
• Mayo elected to defer receipt of shares until either:
  • 30 days after Board separation
  • Company change in control

This Form 4 filing, executed by Earl Douglas as attorney-in-fact on June 20, 2025, reflects standard non-employee director compensation practices. The grant strengthens Mayo's alignment with shareholder interests through increased equity ownership.

Venu Holding Corporation (NYSE American: VENU) filed a Form 8-K dated 18 June 2025 to furnish an updated corporate overview presentation (Exhibit 99.1). The presentation will be used in meetings with prospective investors and strategic partners and highlights the Company’s ongoing Regulation A offering of its Series A 8.0% Cumulative Redeemable Convertible Preferred Stock.

• The preferred shares carry an 8.0% cumulative dividend and are convertible; detailed terms are contained in the Form 1-A offering circular.
• The Company intends to apply to list the Series A Preferred on NYSE American under the ticker â€�VENU.PR Aâ€� after the final closing, but listing approval and market liquidity are not guaranteed.
• Management stresses that the securities are highly speculative; investors could lose their entire investment and may face prolonged illiquidity.
• The furnished material is provided under Item 7.01 (Reg FD); it is not deemed “filedâ€� for liability purposes and is exempt from Section 18 of the Exchange Act.
• Extensive forward-looking-statement disclaimers reference project execution, financial performance and regulatory risks; readers are directed to the Form 1-A risk factors.

No financial results, revenue figures or operational updates were included in this report.

Director Joshua A. Kazam of Allogene Therapeutics (ALLO) received a grant of 94,500 Restricted Stock Units (RSUs) on June 18, 2025. This represents a significant equity compensation award for the board member.

Key details of the RSU grant:

• Each RSU converts to one share of common stock
• Vesting occurs in two equal semi-annual installments over one year from grant date
• Exercise price is $0
• Vesting is contingent on continued service as director

The filing was reported via Form 4 on June 20, 2025, within the required two-business-day window for insider transaction reporting. The transaction represents a direct ownership position and was executed pursuant to the company's director compensation program.

Allogene Therapeutics (Nasdaq: ALLO) filed a Form 8-K reporting the voting results of its 2025 Annual Meeting of Stockholders held on June 18, 2025.

• Director elections: Stockholders re-elected Elizabeth Barrett (131,435,760 FOR), Arie Belldegrun M.D. (150,891,245 FOR) and David Chang M.D. Ph.D. (153,721,017 FOR) as Class I directors, each to serve until the 2028 annual meeting. Broker non-votes totaled 33,512,034 shares.
• Executive compensation: The non-binding advisory vote approved the compensation of named executive officers with 139,947,868 FOR versus 14,233,309 AGAINST and 3,184,237 abstentions.
• Auditor ratification: Ernst & Young LLP was confirmed as independent registered public accounting firm for fiscal 2025 with 190,111,256 FOR and only 414,604 AGAINST.

No other items were presented. The filing contains no updates on financial performance, strategic initiatives, or legal matters.